Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Disintegration piece taken through oral cavity containing Gimeracil and Oteracil Potassium with fluorine being added

A technology of potassium oxonate and oral disintegrant, applied in the field of new pharmaceutical preparations, can solve problems such as affecting patient compliance, and achieve the effects of improving compliance and good taste

Inactive Publication Date: 2005-08-31
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 38 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the gastrointestinal symptoms such as nausea, vomiting, and anorexia in most patients during taking fluterazine belong to mild gastrointestinal reactions, this has largely affected the compliance of patients with medication. The phenomenon of vomiting immediately after treatment has a great impact on the medication of patients. In order to improve the compliance of patients with medication, and to more effectively exert the anti-cancer effect of fluterazine, a better drug administration method was developed. is necessary
However, the strong bitter taste of the three drug components of fluterazine led to the development of fluterazine into orally disintegrating tablets

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0009] Tegafur 2g

[0010] Gimmester 0.58g

[0011] Potassium oxonate 2g

[0012] Hydroxypropyl beta-cyclodextrin 50g

[0013] Mannitol 120g

[0014] Sodium carboxymethyl starch 15g

[0015] Lemon essence 1g

[0016] Appropriate amount of distilled water

[0017] Magnesium Stearate 1g

[0018] Preparation Process:

[0019] Pass tegafur, gimostert and potassium oxonate through a 100-mesh sieve, hydroxypropyl β-cyclodextrin through a 80-mesh sieve, mix well, add a small amount of ethanol to fully grind, and add manna through a 80-mesh sieve after drying Alcohol, sodium carboxymethyl starch and lemon essence, mixed evenly, adding an appropriate amount of binder to granulate, after drying, adding the prescribed amount of lubricant, mixing evenly, and pressing into tablets.

Embodiment 2

[0021] Tegafur 2g

[0022] Gimmester 0.58g

[0023] Potassium oxonate 2g

[0024] Glucosyl α-cyclodextrin 60g

[0025] Mannitol 120g

[0026] Carboxymethyl Cellulose Calcium 15g

[0027] Lemon essence 1g

[0028] Appropriate amount of distilled water

[0029] Magnesium Stearate 1g

[0030] Preparation Process:

[0031] With embodiment 1.

Embodiment 3

[0033] Tegafur 2g

[0034] Gimmester 0.58g

[0035] Potassium oxonate 2g

[0036] β-cyclodextrin 30g

[0037] Mannitol 160g

[0038] Hydroxypropyl Cellulose 20g

[0039] Aspartame 0.5g

[0040] 70% ethanol appropriate amount

[0041] Talc powder 1g

[0042] Preparation Process:

[0043] With embodiment 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An orally-disintegrating tablet of fluterazole for treating tumor contains tegafur, Jimosite and potassium oxyazinate. It has agreeable taste.

Description

technical field [0001] The invention belongs to the new preparation technology of medicine. Background technique [0002] Tegafur (FT, FT-207) is one of the pyrimidine anticancer drugs. It is the prodrug of 5-fluorouracil (5-FU), and has inhibitory effect on most solid tumors. In the body, it can interfere and block the biosynthesis of DNA, RHA and protein, thereby producing its anticancer effect. Basic medical research and clinical observation have proved that tegafur has less toxic and side effects, higher chemotherapy index, less effect on immunosuppression and related immune organs, and is a safe drug that can be used continuously in clinical practice. This product is absorbed through the gastrointestinal tract after oral administration, and the blood concentration reaches the highest peak within 1-3 hours. The duration is longer than that of intravenous administration, so it can exert its better therapeutic effect. It is mainly used for gastric cancer, colon cancer, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/20A61K31/513A61P35/00
Inventor 孙勇
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com